126 related articles for article (PubMed ID: 31063768)
1. Monoamine receptor interaction profiles of 4-aryl-substituted 2,5-dimethoxyphenethylamines (2C-BI derivatives).
Luethi D; Widmer R; Trachsel D; Hoener MC; Liechti ME
Eur J Pharmacol; 2019 Jul; 855():103-111. PubMed ID: 31063768
[TBL] [Abstract][Full Text] [Related]
2. Monoamine receptor interaction profiles of 4-thio-substituted phenethylamines (2C-T drugs).
Luethi D; Trachsel D; Hoener MC; Liechti ME
Neuropharmacology; 2018 May; 134(Pt A):141-148. PubMed ID: 28720478
[TBL] [Abstract][Full Text] [Related]
3. Receptor interaction profiles of novel N-2-methoxybenzyl (NBOMe) derivatives of 2,5-dimethoxy-substituted phenethylamines (2C drugs).
Rickli A; Luethi D; Reinisch J; Buchy D; Hoener MC; Liechti ME
Neuropharmacology; 2015 Dec; 99():546-53. PubMed ID: 26318099
[TBL] [Abstract][Full Text] [Related]
4. Receptor Interaction Profiles of 4-Alkoxy-Substituted 2,5-Dimethoxyphenethylamines and Related Amphetamines.
Kolaczynska KE; Luethi D; Trachsel D; Hoener MC; Liechti ME
Front Pharmacol; 2019; 10():1423. PubMed ID: 31849671
[No Abstract] [Full Text] [Related]
5. Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens.
Rickli A; Moning OD; Hoener MC; Liechti ME
Eur Neuropsychopharmacol; 2016 Aug; 26(8):1327-37. PubMed ID: 27216487
[TBL] [Abstract][Full Text] [Related]
6. Monoamine transporter and receptor interaction profiles of novel psychoactive substances: para-halogenated amphetamines and pyrovalerone cathinones.
Rickli A; Hoener MC; Liechti ME
Eur Neuropsychopharmacol; 2015 Mar; 25(3):365-76. PubMed ID: 25624004
[TBL] [Abstract][Full Text] [Related]
7. Receptor Interaction Profiles of 4-Alkoxy-3,5-Dimethoxy-Phenethylamines (Mescaline Derivatives) and Related Amphetamines.
Kolaczynska KE; Luethi D; Trachsel D; Hoener MC; Liechti ME
Front Pharmacol; 2021; 12():794254. PubMed ID: 35222010
[TBL] [Abstract][Full Text] [Related]
8. Effect of Bulky
Soares BA; Yempala T; Martínez-Afani D; Acevedo-Fuentes W; Brea J; Loza MI; Cimadevila M; Cassels BK
ACS Chem Neurosci; 2024 Feb; 15(3):608-616. PubMed ID: 38241462
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and pharmacological evaluation of N-benzyl substituted 4-bromo-2,5-dimethoxyphenethylamines as 5-HT2A/2C partial agonists.
Hansen M; Jacobsen SE; Plunkett S; Liebscher GE; McCorvy JD; Bräuner-Osborne H; Kristensen JL
Bioorg Med Chem; 2015 Jul; 23(14):3933-7. PubMed ID: 25583099
[TBL] [Abstract][Full Text] [Related]
10. Effects of the new psychoactive substances diclofensine, diphenidine, and methoxphenidine on monoaminergic systems.
Luethi D; Hoener MC; Liechti ME
Eur J Pharmacol; 2018 Jan; 819():242-247. PubMed ID: 29225192
[TBL] [Abstract][Full Text] [Related]
11. Behavioral and neurochemical pharmacology of six psychoactive substituted phenethylamines: mouse locomotion, rat drug discrimination and in vitro receptor and transporter binding and function.
Eshleman AJ; Forster MJ; Wolfrum KM; Johnson RA; Janowsky A; Gatch MB
Psychopharmacology (Berl); 2014 Mar; 231(5):875-88. PubMed ID: 24142203
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological profile of methylphenidate-based designer drugs.
Luethi D; Kaeser PJ; Brandt SD; Krähenbühl S; Hoener MC; Liechti ME
Neuropharmacology; 2018 May; 134(Pt A):133-140. PubMed ID: 28823611
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological profiles of compounds in preworkout supplements ("boosters").
Rickli A; Hoener MC; Liechti ME
Eur J Pharmacol; 2019 Sep; 859():172515. PubMed ID: 31265842
[TBL] [Abstract][Full Text] [Related]
14. Use of the head-twitch response to investigate the structure-activity relationships of 4-thio-substituted 2,5-dimethoxyphenylalkylamines.
Halberstadt AL; Luethi D; Hoener MC; Trachsel D; Brandt SD; Liechti ME
Psychopharmacology (Berl); 2023 Jan; 240(1):115-126. PubMed ID: 36477925
[TBL] [Abstract][Full Text] [Related]
15. Functional selectivity of hallucinogenic phenethylamine and phenylisopropylamine derivatives at human 5-hydroxytryptamine (5-HT)2A and 5-HT2C receptors.
Moya PR; Berg KA; Gutiérrez-Hernandez MA; Sáez-Briones P; Reyes-Parada M; Cassels BK; Clarke WP
J Pharmacol Exp Ther; 2007 Jun; 321(3):1054-61. PubMed ID: 17337633
[TBL] [Abstract][Full Text] [Related]
16. 1-(2,5-Dimethoxy-4-(trifluoromethyl)phenyl)-2-aminopropane: a potent serotonin 5-HT2A/2C agonist.
Nichols DE; Frescas S; Marona-Lewicka D; Huang X; Roth BL; Gudelsky GA; Nash JF
J Med Chem; 1994 Dec; 37(25):4346-51. PubMed ID: 7996545
[TBL] [Abstract][Full Text] [Related]
17. Differential interactions of indolealkylamines with 5-hydroxytryptamine receptor subtypes.
McKenna DJ; Repke DB; Lo L; Peroutka SJ
Neuropharmacology; 1990 Mar; 29(3):193-8. PubMed ID: 2139186
[TBL] [Abstract][Full Text] [Related]
18. Beta-phenylethylamine alters monoamine transporter function via trace amine-associated receptor 1: implication for modulatory roles of trace amines in brain.
Xie Z; Miller GM
J Pharmacol Exp Ther; 2008 May; 325(2):617-28. PubMed ID: 18182557
[TBL] [Abstract][Full Text] [Related]
19. In vitro structure-activity relationship determination of 30 psychedelic new psychoactive substances by means of β-arrestin 2 recruitment to the serotonin 2A receptor.
Pottie E; Cannaert A; Stove CP
Arch Toxicol; 2020 Oct; 94(10):3449-3460. PubMed ID: 32627074
[TBL] [Abstract][Full Text] [Related]
20. Substituted naphthofurans as hallucinogenic phenethylamine-ergoline hybrid molecules with unexpected muscarinic antagonist activity.
Monte AP; Marona-Lewicka D; Lewis MM; Mailman RB; Wainscott DB; Nelson DL; Nichols DE
J Med Chem; 1998 Jun; 41(12):2134-45. PubMed ID: 9622555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
